title: Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men?
authors.forename: David M
authors.initials: DM
authors.lastname: Burger
authors.forename: Marijke C
authors.initials: MC
authors.lastname: Siebers
authors.forename: Patricia W H
authors.initials: PW
authors.lastname: Hugen
authors.forename: Rob E
authors.initials: RE
authors.lastname: Aarnoutse
authors.forename: Yechiel A
authors.initials: YA
authors.lastname: Hekster
authors.forename: Peter P
authors.initials: PP
authors.lastname: Koopmans
mesh_terms: D019380:Anti-HIV Agents / Q000493:pharmacokinetics*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000378:metabolism*; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics*; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D012737:Sex Factors
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D019469:Indinavir